Insmed Takes Follow-On Biologics Push To The Web
This article was originally published in The Pink Sheet Daily
Executive Summary
Not enough understanding of debate, says Insmed exec; economic study to come
You may also be interested in...
Insmed Chief Argues For Five-Year Biologics Exclusivity
Amgen was in the black on Neupogen/Neulasta three years after launch, CEO Allan contends.
Insmed Chief Argues For Five-Year Biologics Exclusivity
Amgen was in the black on Neupogen/Neulasta three years after launch, CEO Allan contends.
FDA To Request Authority To Approve Follow-On Biologics
Agency again seeks user fees to pay for review of generic drug applications and direct-to-consumer TV ads; proposes $984 million budget for human drugs and biologics.